Chantix (Varenicline Tartrate) (Pfizer Inc.) for smoking cessation
n/a
Record ID 32011000793
English
Authors' objectives:
Cigarette smoking is the leading preventable cause of death in the United States, estimated to claim almost 450,000 lives per year. Several therapies have been shown to help smokers to quit, including counseling and social support, the antidepressant bupropion (Zyban®, GlaxoSmithKline), and nicotine replacement therapy (NRT) in the form of gum, patches, nasal spray, inhaler, or lozenges; however, success with these therapies remains low, and many treatments may not be readily available to all smokers who wish to quit. Nicotine is thought to produce its pleasurable and addictive effects by binding to and stimulating a particular receptor, causing the release of a chemical in the brain called dopamine.
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
http://www.hayesinc.com/hayes/crd/?crd=11750
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Nicotinic Agonists
- Quinoxalines
- Smoking
- Smoking Cessation
- Smoking Cessation Agents
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
<p>HAYES, Inc.</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.